You searched for Fibrodysplasia ossificans progressiva (FOP) - Page 2 of 8

- 24 Août 2023

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Paris and Montréal, 25 February 2019 – Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage ...

- 26 Mai 2023

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

PARIS, FRANCE, 26 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Product...

- 26 Mai 2023

Ipsen reçoit un avis négatif du Comité des médicaments à usage humain (CHMP) à la suite du réexamen du palovarotène en tant que premier traitement de FOP au sein de l’Union européenne (UE)

PARIS, FRANCE, le 26 mai 2023 – Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd'hui que, malgré le réexamen du palovarotène pour le traitement potentiel de la FOP, une maladie osseuse ultra-rare, le CHMP de l'Agence eu...

- 19 Juillet 2023

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

PARIS, FRANCE, 19 July 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has followed guidance provided by the Committee for Medicinal Products for Human Use (CHMP) in May this year, and has not granted marketing autho...

- 27 Janvier 2023

Ipsen receives CHMP negative opinion for palovarotene as a treatment for fibrodysplasia ossificans progressiva in E.U.

PARIS, FRANCE, 27 January 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investi...

- 16 Août 2023

Les autorités réglementaires américaines (FDA) approuvent le médicament d’Ipsen SOHONOS™ (capsules de palovarotène), premier et unique traitement pour les personnes atteintes de fibrodysplasie ossifiante progressive

PARIS, FRANCE, le 16 août 2023 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui l'approbation par les autorités réglementaires américaines (Food and Drug Administration, FDA) de SOHONOS™ (capsules de palovarotène) en tant que rétinoïde...

- 29 Juin 2023

Ipsen annonce les résultats positifs du comité consultatif de la FDA sur le palovarotène expérimental pour la fibrodysplasie ossifiante progressive

« Nous sommes heureux du vote majoritaire du Comité consultatif de la FDA en faveur du palovarotène, qui témoigne du potentiel de ce médicament dans la prise en charge des consequences graves de la FOP. La mobilité est considérablement restreinte ch...

- 12 Mai 2023 - 4 mn de lecture

Understanding the true impact of living with FOP

This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23, ...

- 16 Mars 2023

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

PARIS, FRANCE, 16 March 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational pa...

- 08 Février 2024

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

PARIS, FRANCE, 8 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023....

1 2 3 4 … 7

Say	Action
“Show menu”	Open the accessibility menu
“Close menu”	Close the accessibility menu
“Disable voice navigation”	Stops voice command mode
“List Headings”	Provides a quick overview of all headings
“List landmarks”	Displays the main structural regions of a webpage
“List links”	Displays all hyperlinks on the page
“Tab next”	Moves focus to the next interactive element
“Tab back”	Moves focus to the previous interactive element
“Follow/click”	Activates the currently focused link or button
“Reload page”	Refreshes the current webpage
“Home page”	Returns the user to the home page
“Previous page”	Navigates back to the previously visited page
“Zoom in”	Increases the zoom level
“Zoom out”	Decreases the zoom level
“Move left”	Shifts the cursor to the left
“Move right”	Shifts the cursor to the right
“Move up”	Moves the cursor upward
“Move down”	Moves the cursor downward
“Move to beginning”	Moves the cursor to the beginning of the text
“Move to end”	Moves the cursor to the end of the text
“Select all”	Selects all text in the focused field, or all page text when no field is focused
“Clear all selection”	Removes the current highlight without deleting text. It also works after “Select all”.
“Type [text]”	Inserts [text] into the focused field. Say “space”, “blank space”, or “white space” between words, for example “Type hello space world”.
“Clear input”	Removes or resets text in the currently focused input field
“Cut”	Removes selected text and places it on the clipboard
“Copy”	Copies selected text to the clipboard without removing it
“Paste”	Reads clipboard text and inserts it into the focused editable field
“Lowercase”	Converts the selected text to lowercase.
”Uppercase”	Converts the selected text to uppercase
“Delete selected text”	Removes the currently highlighted or selected text
“Skip to main content”	Moves focus to the main content region
“Skip to navigation”	Allows users to quickly move to the main navigation menu
“Skip to footer”	Allows users to jump directly to the footer section of the webpage
“Show number on link”	Displays numbered labels for links on the page to simplify voice-based navigation
“Remove number from link”	Removes every visible voice number label from links. Use this after “Show numbers on links”.
“Go to [number]”	Moves focus to the link with that displayed number without opening it. First say “Show numbers on links”.
“Click [number]”	Opens the link with that displayed number. First say “Show numbers on links”, then say “Click 1”, “Click number 2”, or another displayed number.

Résultats de recherche